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Background: Focal adhesion kinase (FAK) and 
CUB-domain containing protein 1 (CDCP1) are 
Src family kinase (SFK) substrates. 
Results: SFK switching between FAK-Y861 
and CDCP1-Y734 is induced by increased 
CDCP1 expression and changes in cell 
attachment. 
Conclusion: SFK switching between FAK and 
CDCP1 may be relevant to malignant 
transformation. 
Significance: Targeting of this switch may be a 
rational approach to treat diseases such as 
cancer. 
 
SUMMARY 
Reciprocal interactions between Src family 
kinases (SFKs) and focal adhesion kinase 
(FAK) are critical during changes in cell 
attachment. Recently it has been recognised 
that another SFK substrate, CUB-domain 
containing protein 1 (CDCP1), is 
differentially phosphorylated during these 
events. However, the molecular processes 
underlying SFK-mediated phosphorylation of 
CDCP1 are poorly understood. Here we 
identify a novel mechanism in which FAK 
tyrosine (Y) 861 and CDCP1-Y734 compete 
as SFK substrates and demonstrate cellular 
settings in which SFKs switch between these 
sites. Our results show that stable CDCP1 
expression induces robust SFK-mediated 
phosphorylation of CDCP1-Y734 with 
concomitant loss of p-FAK-Y861 in adherent 
HeLa cells. SFK substrate switching in these 
cells is dependent on the level of expression of 
CDCP1 and is also dependent on CDCP1-
Y734 but is independent of CDCP1-Y743 and 
-Y762. In HeLa-CDCP1 cells, engagement of 
SFKs with CDCP1 is accompanied by an 
increase in phosphorylation of Src-Y416 and 
a change in cell morphology to a fibroblastic 
appearance dependent on CDCP1-Y734. SFK 
switching between FAK-Y861 and CDCP1-
Y734 also occurs during changes in adhesion 
of colorectal cancer cell lines endogenously 
expressing these two proteins. Consistently, 
increased p-FAK-Y861 levels and a more 
epithelial morphology are seen in colon 
cancer SW480 cells silenced for CDCP1. 
Unlike protein kinase C δ, FAK does not 
appear to form a trimeric complex with Src 
and CDCP1. These data demonstrate novel 
aspects of the dynamics of SFK-mediated cell 
signalling that may be relevant during cancer 
progression. 
 
INTRODUCTION 
Src family kinases (SFKs), comprising the non-
receptor tyrosine kinases Src, Yes, Fyn, Lyn, 
Lck, Hck, Fgr, Blk and Yrk (1), are essential 
mediators of signals required for a range of 
physiological processes (2). In addition, over-
expression and increased activity of Src in 
human epithelial cancers is common and 
proposed to play a key role in cancer 
progression, particularly during later stages 
when tumour cells acquire metastatic abilities 
(3-7).  
 
SFK activation can be achieved by a number of 
mechanisms including phosphorylation, intra-
molecular protein-protein interactions and 
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interactions with binding proteins (8). 
Regulation by phosphorylation is primarily 
controlled at two tyrosine (Y) residues. 
Phosphorylation of Y527 causes a closed and 
inactive confirmation while its 
dephosphorylation induces a conformational 
change causing activation. Maximal kinase 
activity requires auto-phosphorylation of Y416 
(2). Another mechanism of Src activation is by 
displacement of intramolecular interactions at its 
SH2 and SH3 domains by higher affinity ligands 
such as the non-receptor tyrosine kinase focal 
adhesion kinase (FAK) (8-9), another protein 
upregulated and/or activated in a range of human 
malignancies that plays a role in cellular 
processes such as adhesion, migration and cell 
death (10-12). In particular FAK has a key role 
in integrin mediated signalling during cell 
adhesion (13). Upon binding of integrins, FAK 
becomes activated through autophosphorylation 
at Y397 which allows for high affinity binding 
of Src at this site (14-15) inducing 
conformational changes and further 
phosphorylation of FAK, mediated by SFKs at 
Y407, Y576/577, Y861 and Y925 (16-18).  
 
Several recent studies have recognised the cell 
surface glycoprotein CUB-domain containing 
protein 1 (CDCP1) as a SFK substrate (19-23) 
that promotes cancer associated cellular changes 
in vitro and in animal models (23-30). 
Phosphorylation of CDCP1 by SFKs is thought 
to occur initially at Y734 followed by further 
SFK-mediated phosphorylation at Y743 and 
Y762 and recruitment of protein kinase C δ 
(PKCδ) at this last site (21, 23). Formation of a 
trimeric protein complex of SFKs, CDCP1 and  
PKCδ , plays a critical role in facilitating a 
CDCP1 mediated anti-apoptotic cell phenotype 
in vitro (30). The potential functional 
importance of phosphorylation of CDCP1 by 
SFKs is further indicated by the observation that 
it is induced by a number of stimuli including 
loss of cell adhesion (23, 31-32), cleavage by 
trypsin-fold serine proteases (20, 33), cell 
detachment during mitosis (22, 31-32) and cell 
shedding (32).  
 
The in vivo importance of CDCP1 
phosphorylation has been indicated by reports 
showing that p-CDCP1-Y734 is expressed by 
gastric cancer 44As3 cells undergoing peritoneal 
dissemination in mice and not by surrounding 
stroma and that p-CDCP1-Y734 levels are 
markedly upregulated in ~30% of human 
scirrhous-type gastric cancers (30). This residue 
is also required for CDCP1-mediated 
experimental metastasis of melanoma cells in 
mice (25). In addition, another CDCP1 tyrosine, 
Y743, is phosphorylated in a wide range of 
cancers but not in normal cells not undergoing 
mitosis or shedding (32). 
 
To examine the role of tyrosine phosphorylation 
in CDCP1 biology we have generated HeLa 
cells stably expressing this protein or a mutant 
lacking the critical SFK phosphorylation site at 
Y734. CDCP1 was basally phosphorylated in 
these cells and, unexpectedly, its expression 
eliminated SFK-mediated phosphorylation of 
FAK-Y861. CDCP1 expression was 
accompanied by a change in HeLa cell 
morphology that was restored, together with 
phosphorylation of FAK-Y861, in HeLa cells 
expressing CDCP1-Y734F and also when the 
activity of SFKs was selectively inhibited. Our 
data suggest that over-expression of CDCP1 can 
induce SFK substrate switching from FAK-
Y861 to CDCP1-Y734. Importantly, we also 
observed this switching in colorectal cancer cell 
lines endogenously expressing FAK and 
CDCP1. However, switching in these cells was 
mediated by changes in cell anchorage. These 
data highlight two settings under which SFKs 
can switch between FAK-Y861 and CDCP1-
Y734. As both settings (increased expression of 
CDCP1 and changes in cell adhesion) occur 
during cancer progression, these observations 
may be useful in understanding SFK•CDCP1-
mediated mechanisms occurring during 
malignant transformation. 
 
EXPERIMENTAL PROCEDURES 
Antibodies and reagents—Antibodies were from 
the following suppliers: rabbit anti-matrix 
metalloproteinase-9 (MMP-9; #ab38898) 
antibody from Abcam (Cambridge, MA); rabbit 
polyclonal antibody against unspecified C-
terminal residues of CDCP1 from Cell Signaling 
Technology (CST; Danvers, MA; #4115); goat 
anti-lipocalin2 antibody (#AF1757) and a stem 
cell array kit (#ARY010) from R&D Systems 
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(Bio-Scientific Pty Ltd, Gymea, Australia); 
rabbit anti-Src (#2108) and anti-p-Src (#2101) 
antibodies from CST, rabbit anti-p-FAK-Y861 
antibody (#44626G) that detects both p-CDCP1-
Y734 and p-FAK-Y861 (20), mouse anti-smooth 
muscle actin (#18-0106) and anti-cytokeratin-8/-
18 (#18-0213) antibodies, and goat anti-mouse 
Alexa Fluor 488 and 647 secondary antibodies 
from Invitrogen (Mulgrave, Australia); rabbit 
anti-FLAG epitope (DYKDDDDK) and mouse 
anti-tubulin antibodies from Sigma (Castle Hill, 
Australia); monoclonal anti-phosphotyrosine 
antibody PY20 (#525295) from Calbiochem (La 
Jolla, CA); monoclonal anti-glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) antibody 
from Chemicon International (Boronia, 
Australia); antibodies against FAK (#05-537) 
and p-FAK-Y397 (#05-1144) from Millipore 
(North Ryde, Australia); and HRP-conjugated 
secondary antibodies from Thermo Fisher 
Scientific (Scorseby, Australia). Anti-CDCP1 
monoclonal antibodies 41-2 (19, 24, 34) and 
10D7 (24) were previously described. Control 
immunoglobulins (IgGs) were from Sigma and 
Invitrogen. Protein A/G agarose and Complete 
EDTA-free protease inhibitor were from Roche 
Applied Sciences (Castle Hill, Australia). G418 
and puromycin were from InvivoGen (San 
Diego, CA) and the SFK selective inhibitor 
SU6656 (35) was from Invitrogen. Annexin V 
conjugated Alexa Fluor 647 was from Biolegend 
(Australian Biosearch, Karrinyup, Australia). All 
other reagents were from Sigma. The CDCP1-
FLAG encoding expression construct has been 
described previously (33). Site-directed 
mutagenesis, to introduce the CDCP1 mutation 
Y734F, was performed using Pfu Ultra 
polymerase (Stratagene, La Jolla, CA). The 
sequence of constructs was confirmed by DNA 
sequencing at the Australian Genome Research 
Facility (St. Lucia, Australia). pLKO.1 lentiviral 
shRNA constructs targeting CDCP1 were 
purchased from OpenBiosystems and the 
pLKO.1-scramble control was from Addgene 
(Cambridge, MA). 
 
Cell culture and transfections—Cells were 
purchased from ATCC (Manassas, VA). 
Untransfected HeLa cells and colon cancer 
CaCo2, HCT116, SW480 and SW620 cells were 
cultured in “complete media” of DMEM 
supplemented with 10% FCS, 100 units/ml 
penicillin and 100 μg/ml streptomycin 
(Invitrogen) in a 5% CO2 humidified atmosphere 
at 37°C. All cells were passaged exclusively 
non-enzymatically using Versene (Invitrogen) or 
500 µM EDTA in PBS. HeLa cells were 
transfected with pcDNA3.1 (vector) or CDCP1-
FLAG or CDCP1-FLAG-Y734F expression 
constructs using Lipofectamine 2000 
(Invitrogen). Stably transfected cells were 
selected in G418 (800 µg/ml) containing media 
for 10 days before clonal selection by 
fluorescence activated cell sorting using the anti-
CDCP1 monoclonal antibody 10D7 and 
expansion and maintenance in G418 containing 
media. Cells were examined by transmitted light 
microscopy analysis using a Nikon Eclipse 
TE2000-U microscope.  
 
Lentiviral shRNA gene silencing—CDCP1 
expression was suppressed using a pLKO.1 
lentiviral shRNA knock-down system 
(OpenBiosystems, Millennium Science, Surrey 
Hills, Australia) with a scramble shRNA 
construct (Addgene, Cambridge, MA) as a 
control. To generate lentivirus, the pLKO.1 
shRNA construct and packaging plasmids 
(pCMV-VSVG and pCMV-dR8.2-dvpr) were 
cotransfected into HEK293T cells with 
Lipofectamine 2000 (Invitrogen). The 
conditioned media was collected 48 and 72 hrs 
post-transfection and pooled, followed by 
filtration through a 0.45 µm filter. Filtered 
conditioned media was used to infect target cells 
in the presence of 8 µg/ml of hexadimethrine 
bromide (Sigma). Cells were initially infected 
for 3 hours, allowed to recover overnight in 
complete media and then transfected a second 
time overnight. After washing cells were 
cultured for 24 hrs in complete media before 
selection in puromycin (2 µg/ml) containing 
medium for 1 week. Gene silencing efficiency 
was assessed by Western blot analysis. 
 
Cell treatments—To examine the effect of 
inhibiting SFK activity on cell morphology, cells 
were detached with Versene then washed with 
PBS, counted and seeded at 2x105 cells/T25 
flask in complete media containing G418 (700 
µg/ml) in the presence of either SU6656 (10 
μM) or vehicle (0.075% v/v DMSO). After 1 hr 
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this media was replaced with complete media 
containing G418 (700 µg/ml). After a total of 24 
hrs cell morphology was assessed by light 
microscopy using an Nikon Eclipse TE2000-U 
microscope as described below. The level of cell 
death induced by SU6656 treatment was 
examined by flow cytometry analysis of annexin 
V stained cells as described below. To examine 
the effect of SFK inhibition on phosphorylation 
of CDCP1-Y734 and FAK-Y861, lysates were 
collected for Western blot analysis (described 
below) of HeLa-vector, HeLa-CDCP1 and 
HeLa-CDCP1-Y734F cells treated with vehicle 
(0.37% v/v DMSO) or increasing concentrations 
of SU6656 (0.1, 0.27, 1, 2.7 and 10 µM) for 60 
minutes. To examine changes in phosphorylation 
of CDCP1-Y734 and FAK-Y861, the 
adhesion/de-adhesion status of HeLa-CDCP1 
cell clone 2 and 3 and colon cancer HCT116 and 
SW480 cells was modulated. For adhesion 
experiments cells were cultured in DMEM to 
50% confluence then serum-starved for 24 hours 
before detachment with 500 µM EDTA in PBS. 
After 30 minutes in suspension cells were 
allowed to re-adhere to plastic for periods of up 
to 45 minutes. Cells in suspension were then 
collected from media by low speed 
centrifugation and lysed in buffer containing 
protease inhibitor mixture, 2 mM sodium 
vanadate, 10 mM sodium fluoride, Triton X-100 
(1%), 50mM Tris-HCl (pH 7.4), and NaCl (150 
mM). Adhered cells were lysed in situ in the 
same buffer and after clearance by centrifugation 
were combined with lysates obtained from cells 
in suspension. For de-adhesion experiments cells 
were cultured to 50% confluence then serum-
starved for 24 hours before incubation with 500 
µM EDTA in PBS for periods of up to 45 
minutes. Adhered and suspended cells were 
collected and lysed as described above. 
 
Quantification of cell morphology—Images of 
fields of cells acquired by light microscopy 
using a 10x objective on a Nikon Eclipse 
TE2000-U microscope were analysed using 
MetaMorph Imaging Software (Molecular 
Devices, Bio-Strategy Pty Ltd, Hawthorne East, 
Australia) to determine the length of the short 
and long axis of each cell. Based on a previously 
reported approach (36), the shape factor for each 
cell was determined as the ratio of short axis to 
long axis. For epithelial shaped cells this value 
approaches 1 and for elongated, fibroblastic cells 
it approaches zero. Cells were grouped into one 
of two categories based on shape factor (0 to 
0.49 and 0.5 to 1) and these categories were 
graphed against the proportion of cells in each 
category. For analysis of HeLa cells stably 
transfected with vector or expression constructs 
encoding either CDCP1 or CDCP1-Y734F, at 
least 50 cells were analysed. For cells treated 
with SU6656 at least 80 cells were analysed per 
experiment and experiments were performed 3 
times. Statistical analysis for change in cell 
morphology was performed using the Student’s 
t-test with a 95% confidence interval using 
SigmaPlot 11 (Systat Software, Inc., San Jose, 
CA). A P value < 0.05 was considered 
significant and is indicated by an asterisk in 
Figure 1. 
 
Flow cytometry—To assess CDCP1 expression 
levels, cells grown to 70-90% confluence were 
de-adhered with Versene then stained for 30 
minutes on ice with anti-CDCP1 antibody 10D7 
(3 μg/ml) in PBS. After washes with ice cold 
PBS, cells stained with 10D7 were incubated for 
30 minutes on ice with a goat anti-mouse Alexa 
Fluor 488 secondary antibody (1:750 dilution). 
After washes with ice cold PBS a minimum of 
10,000 cells were analysed using a Cytomics 
FC-500 MPL flow cytometer (Beckman Coulter; 
Gladesville, Australia). To assess the level of 
cell death caused by SU6656 treatment, treated 
and untreated cells were stained with annexin V 
conjugated Alexa Fluor 647 as previously 
described (37) and analysed using an LSR II 
flow cytometr (BD Biosciences, San Jose, CA). 
Data plots generated from flow cytometry 
analyses are representative of 3 independent 
experiments performed in triplicate. 
 
Cell lysis, immunoprecipitation, Western blot 
and stem cell array analysis—For experiments 
other than adhesion/de-adhesion assays whole 
cell lysates were collected in a buffer containing 
protease inhibitor mixture, 2 mM sodium 
vanadate, 10 mM sodium fluoride and either 
Triton X-100 (1%), 50mM Tris-HCl (pH 7.4) 
and NaCl (150mM), or CHAPS (1%), PBS (pH 
7.4) and MgCl2 (2 mM). Protein concentration 
was determined by microbicinchoninic acid 
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assay (Thermo Scientific). For 
immunoprecipitations, total protein (500 μg) was 
pre-cleared for 2 hours at 4°C by end to end 
rotation with immobilised Protein A/G beads. 
After centrifugation the supernatant was mixed 
with the immunoprecipitating antibody (5 μg) 
and incubated overnight at 4°C by end to end 
rotation. Fresh aliquots of Protein A/G beads 
were then added, and the mixture was incubated 
for 4 h at 4 °C by end to end rotation. The beads 
were then washed three times in cell lysis buffer 
then associated proteins were eluted into 
Laemmli sample buffer. Cell lysates and 
immunoprecipitated proteins were separated by 
SDS-PAGE under either non-reducing (for 
Western blot analysis using 10D7 as primary 
antibody) or reducing conditions, and transferred 
to nitrocellulose membranes, which were 
blocked in 5% skim milk in Tris-buffered saline 
containing 0.1% Tween 20 (TBS-T). 
Membranes were incubated with primary 
antibodies diluted in blocking buffer for 1-3 
hours at room temperature, washed with TBS-T, 
and then incubated with species-appropriate 
HRP-conjugated secondary antibodies for 60 
minutes. Following washes, membranes were 
incubated with SuperSignal West Pico Substrate 
(Thermo Fisher Scientific) then exposed to film. 
Consistent protein loading and transfer was 
determined by reprobing membranes stripped in 
Restore Western blot stripping buffer (Pierce) 
with either an anti-GAPDH or anti-tubulin 
antibody. Densitometry analysis was performed 
using Image-J. P values were determined from 4 
experiments using one-tailed Student’s t-test 
with a 95% confidence interval using GraphPad 
Prism. A P value < 0.05 was considered 
significant and is indicated by an asterisk in 
Figure 4. 
 
To assess the expression of stem cell markers 
HeLa-vector, HeLa-CDCP1 and HeLa-CDCP1-
Y734F cells were seeded in T75 flasks 48 hours 
before lysates were prepared. Cells were 
harvested at a confluence of 70% using an array 
kit lysis buffer containing 10 µg/ml aprotinin 
and 1 x protease inhibitor cocktail. Stem cell 
arrays were hybridised with  175 µg of total 
protein according to the instructions of the 
manufacturer and then exposed to film. 
 
Confocal microscopy—Cells grown on sterile 
coverslips were washed in PBS, fixed in 4% 
formaldehyde in PBS for 15 min at room 
temperature, rinsed twice with PBS then 
permeabilised with 0.1% Triton X-100 in PBS 
for 15 minutes at room temperature. After 
blocking in 0.5% BSA for 30 minutes cells were 
incubated with the mouse anti-CDCP1 antibody 
41-2 (5 μg/ml) for 45 minutes at room 
temperature followed by incubation with a rabbit 
anti-Src antibody (1:100 dilution; CST #2108). 
The cells were then washed twice with PBS and 
incubated with species specific Alexa Flour-
conjugated secondary antibodies (1:750 dilution) 
for 30 minutes at room temperature. Actin and 
cell nuclei were stained by incubation for 10 
minutes at room temperature with a PBS 
solution containing Alexa Fluor 488 phalloidin 
and DAPI (1:1000 dilution). Following washes 
with PBS, coverslips were mounted on slides, 
and cells imaged with a Leica TCS SP5 confocal 
microscope (Leica Microsystems, Sydney, 
Australia). Images were processed and displayed 
using Corel Draw (Corel Pty Ltd; Sydney, 
Australia). 
 
RESULTS 
CDCP1 expression alters HeLa cell morphology 
dependent on CDCP1-Y734, the SFK binding 
site—To examine the function of Y734 of 
CDCP1, HeLa cells were stably trasfected with 
vector (HeLa-vector) or expression constructs 
encoding CDCP1-FLAG (HeLa-CDCP1) or 
CDCP1-FLAG mutated at Y734 (HeLa-CDCP1-
Y734F) which is the primary site for SFK 
binding (21). Western blot and flow cytometric 
analysis, shown in Figure 1A and 1B, 
respectively, indicated high and uniform 
expression of CDCP1 and CDCP1-Y734F. 
These data were obtained from combination of 3 
clones for each stable cell type, however the 
same data was obtained from analysis of the 
individual clones (not shown). In these cells 
CDCP1 is produced exclusively with a 
molecular weight of 135 kDa with no evidence 
of a lower molecular weight CDCP1 species 
variously reported at 70-85 kDa for some cell 
lines (19-20, 22-23). It has previously been 
shown that the difference in the predicted 
molecular weight of CDCP1 (~92 kDa) and its 
apparent molecular weight of 135 kDa is due in 
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large part to 35-40 kDa of N-linked glycans 
(19). Consistent with previous reports, Src, 
CDCP1 and PKCδ form a complex that is 
dependent on CDCP1-Y734 as mutation of this 
site completely abolished PKCδ binding and 
markedly reduced Src binding (Fig 1C). In line 
with the decreased binding of Src to CDCP1-
Y734F, we found that tyrosine-phosphorylation 
of CDCP1 was only detectable in HeLa-CDCP1 
but not in  HeLa-CDCP1-Y734F cells (Fig 1C). 
Of note, microscopy analysis revealed that 
CDCP1 expression altered the morphology of 
HeLa cells from an epithelial appearance, 
characteristic of parental and vector transfected 
cells, to an elongated, spindle-like fibroblastic 
morphology (Fig 1D). Quantitative analysis of 
the morphology of these cells indicated that 
there was a statistically significant difference 
between CDCP1 expressing HeLa cells and 
HeLa-vector and HeLa-CDCP1-Y734F cells; 
~55% of HeLa-CDCP1 cells had an elongated 
morphology in comparison with ~20% of HeLa-
vector and HeLa-CDCP1-Y734F cells (Fig 1D, 
graph). CDCP1-Y734 was required for this 
change as the morphology of HeLa-CDCP1-
Y734F cells was reminiscent of parental and 
vector cells (Fig 1D, images and graph). 
Significantly, mutation of two other SFKs 
phosphorylation sites, CDCP1-Y743 and -Y762  
(21, 23), did not cause a reversion to an 
epithelial morphology (Supp Fig 1). 
 
As the morphological change of HeLa-CDCP1 
cells is reminiscent of an epithelial to 
mesenchymal transition (EMT), we analysed the 
expression of markers of epithelial and 
mesenchymal cells in the generated cell lines. 
Western blot analysis using antibodies against 
MMP-9, smooth muscle actin and lipocalin2 
(mesenchymal markers) and cytokeratin-8 and -
18 (epithelial markers) indicated that CDCP1 
expression did not alter expression of these 
markers of EMT (Supp Fig 2A). As it has 
previously been noted that EMT can generate 
cells with stem cell properties (38), we also 
probed an array containing antibodies against 15 
pluripotent stem cell markers with lysates from 
HeLa-vector, HeLa-CDCP1 and HeLa-CDCP1-
Y734F cells. No changes in any of the markers 
were observed (Supp Fig 2B). These data 
suggest that the altered morphology of HeLa 
cells induced by CDCP1 expression is not due to 
an EMT.   
 
Knock-down of CDCP1 reverts HeLa-CDCP1 
cells to an epithelial morphology—To further 
address the role of CDCP1 in the observed 
change in cell morphology, we reduced 
expression of CDCP1 using an shRNA knock-
down approach. Using a virus mediated protocol 
we generated stable polyclonal cells. Anti-
CDCP1 Western blot analysis indicated that 
CDCP1 and CDCP1-Y734F had been 
specifically reduced by greater than 95% (Fig 
2A).  As shown in Figure 2B and Supplemental 
Figure 3, light microscopy analysis 
demonstrated that knockdown of CDCP1 caused 
reversion of HeLa-CDCP1 cell shape to an 
epithelial morphology. Cell morphology was 
unaffected by the scrambled control and 
knockdown of CDCP1-Y734F (Fig 2B and Supp 
Fig 3). 
 
CDCP1-induced Hela cell morphology change 
requires SFK activity—To directly examine 
whether SFK activity is required for the 
observed change in HeLa cell morphology, 
HeLa-CDCP1 cells were either untreated or 
treated with the SFK-selective inhibitor SU6656 
(35) at a concentration of 10 μM. In these 
experiments cells were plated in the presence of 
SU6656 (or vehicle for controls). Treatment 
continued for 1 hr then the media was changed 
to normal growth media. After a recovery period 
of 23 hrs cells were photographed. As shown in 
Figure 3A and Supplemental Figure 4, SU6656 
treatment had no impact on HeLa-vector and 
HeLa-CDCP1-Y734 cells but caused the 
reversion of HeLa-CDCP1 cell morphology 
from an elongated, spindle-like morphology to 
an epithelial appearance. Quantitative analysis of 
cell morphology indicated that HeLa-vector, 
HeLa-CDCP1 and HeLa-CDCP1-Y734F cells 
shared common morphological features after 
SU6656 treatment (Fig 3B; compare with graph 
in Fig 1D). In addition, flow cytometry analysis 
of annexin V stained cells indicated that SU6656 
treatment did not alter the proportion of cells 
undergoing apoptosis indicating that the 
SU6656-mediated altered morphology of HeLa-
CDCP1 cells was not due to a cytotoxic effect 
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(Fig 3C). These data  indicate that altered HeLa-
CDCP1 cell morphology requires SFK activity.  
 
Altered HeLa-CDCP1 cell morphology is 
accompanied by increased phosphorylation of 
Src-Y416 without altering cellular localisation 
of Src—Binding of Src to substrates can 
reciprocally increase Src activation (39-41). To 
examine whether CDCP1 expression increased 
Src activation, we performed anti-pSrc-Y416 
Western blot analysis of lysates from HeLa-
vector, HeLa-CDCP1 and HeLa-CDCP1-Y734F 
cells. As shown in Figure 4A, this analysis 
indicated that CDCP1 expression in HeLa cells 
results in a ~40% increase in phosphorylation of 
Src-Y416 and that this statistically significant 
increase is dependent on Y734 of CDCP1. We 
also used confocal microscopy to determine 
whether changes in cell morphology were 
associated with differences in the localisation of 
Src or CDCP1. As shown in Figure 4B (blue), 
CDCP1 localisation was unaffected by mutation 
of CDCP1-Y734 with this protein being 
localised primarily at the cell surface. Similarly, 
Src staining was not altered by CDCP1 or 
CDCP1-Y734F expression with this protein 
present throughout the cytoplasm of HeLa-
vector, HeLa-CDCP1 and HeLa-CDCP1-Y734F 
cells with evidence of membrane accentuation in 
each cell type (Fig 4B red). Phalloidin staining 
indicated that actin localisation was similar in 
unstimulated HeLa-vector and HeLa-CDCP1-
Y734F cells while HeLa-CDCP1 cells exhibited 
some evidence of juxta-plasma membrane 
accentuation of actin localisation, although this 
was heterogeneous amongst cell populations 
(Fig 4B, green). DAPI staining indicated that 
cell nuclei were not altered by expression of 
CDCP1 or CDCP1-Y734F (Fig 4B, inset).  
 
CDCP1-Y734 is phosphorylated in preference to 
FAK-Y861 in HeLa-CDCP1 cells—To directly 
examine the phosphorylation of CDCP1-Y734, 
we performed Western blot analysis with an 
anti-p-FAK-Y861 antibody that also efficiently 
recognises CDCP1-Y734; this antibody detects 
p-FAK-Y861 at ~125 kDa and p-CDCP1-Y734 
at ~135 kDa (20, 33). As expected, analysis of 
lysates from HeLa-vector, HeLa-CDCP1 and 
HeLa-CDCP1-Y734F cells detected p-CDCP1-
Y734 exclusively in HeLa-CDCP1 cells (Fig 
5A). However, whereas p-FAK-Y861 was 
detected in lysates of HeLa-vector and HeLa-
CDCP1-Y734F cells, it was not present in 
HeLa-CDCP1 cells even though Western blot 
analysis indicated that total FAK levels were the 
same in each cell type (Fig 5A, compare top 
panel with the panel second from top). 
Interestingly, HeLa cells stably expressing 
CDCP1-Y743F or CDCP1-Y762F  also had high 
levels of p-CDCP1-Y734 with no evidence of p-
FAK-Y861 (Supp Fig 5). Of further interest, 
stable expression of CDCP1 had no significant 
effect on phosphorylation of FAK-Y397 (Fig 
5A), an auto-phosphorylation site, 
phosphorylation of which creates a high affinity 
binding site for SH2 domain containing proteins 
including Src (14). These data suggest that 
CDCP1-Y734 is phosphorylated in preference to 
FAK-Y861 in HeLa-CDCP1 cells. This proposal 
is supported by analysis of cells silenced for 
CDCP1 (characterised in Figure 2). Western blot 
analysis using the anti-p-FAK-Y861 antibody 
indicated that silencing of CDCP1 in HeLa-
CDCP1 cells resulted in phosphorylation of 
FAK-Y861 to levels seen in HeLa-vector and 
HeLa-CDCP1-Y734F cells (Fig 5B). To confirm 
the role of SFKs in these tyrosine 
phosphorylation events we treated HeLa-vector, 
HeLa-CDCP1 and HeLa-CDCP1-Y734F cells 
with increasing concentrations of the SFK-
selective inhibitor SU6656 for 1 hr (the same 
treatment period used for cells shown in Figure 
3). As shown in Figure 5C, Western blot 
analysis of lysates from these cells, using the 
anti-p-FAK-Y861 antibody, demonstrated that 
SU6656 inhibited phosphorylation of both FAK-
Y861 and CDCP1-Y734 in a dose dependent 
manner.  
 
SFK phosphorylation of CDCP1-Y734 and FAK-
Y861 in HeLa-CDCP1 cells is inversely related 
and depends on the level of expression of 
CDCP1 but CDCP1 and FAK do not interact—
During the generation of HeLa-CDCP1 cells we 
obtained clones expressing this protein at 
varying levels. These were used to investigate 
further the relationship between phosphorylation 
of CDCP1-Y734 and FAK-Y861. As shown in 
Figure 6A, by flow cytometry analysis, using the 
anti-CDCP1 monoclonal antibody 10D7, four 
HeLa-CDCP1 cell clones (numbered 1 to 4) 
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expressed CDCP1 at increasing levels on the cell 
surface. Expression levels ranged from barely 
detectable (clone 1 in comparison with HeLa-
vector cells), to approximating the levels seen in 
endogenous expressing prostate cancer PC3 cells 
(clone 2), with two other clones (number 3 and 
4) expressing CDCP1 at progressively higher 
levels. To examine the relationship between 
phosphorylation of CDCP1-Y734 and FAK-
Y861 we examined these cells by Western blot 
analysis using the anti-p-FAK-Y861 antibody 
that cross reacts with p-CDCP1-Y734 (20). This 
analysis demonstrated that the level of 
phosphorylation of CDCP1-Y734 in these cells 
directly correlated with the level of expression 
of CDCP1 while the level of phosphorylation of 
FAK-Y861 was inversely correlated with the 
level of expression of CDCP1 (Fig 6B). 
Phosphorylation of FAK-Y397 was unaffected 
by CDCP1 expression levels. These data suggest 
that SFKs switch between CDCP1-Y734 and 
FAK-Y861 as phosphorylation substrates 
depending on the level of CDCP1 expressed by 
HeLa-CDCP1 cells. As shown in Figure 6C, the 
degree of a fibroblastic morphology present in 
HeLa-CDCP1 clones 1 to 4 was consistent with 
the level of expression of CDCP1; the lower the 
level of CDCP1 expression the more epithelial 
the cell morphology and the higher the level of 
CDCP1 expression the more mesenchymal the 
cell morphology. 
 
As shown in Figure 1C, Src, CDCP1 and PKCδ 
form a complex in adherent HeLa-CDCP1 cells 
and these interactions are dependent on CDCP1-
Y734. As our data also indicate that SFKs 
switch between CDCP1-Y734 and FAK-Y861 
and this switching is dependent on CDCP1-
Y734, we examined whether Src, CDCP1 and 
FAK form a similar complex. Our Western blot 
analysis of immunoprecipitations performed 
with an anti-FLAG antibody indicated that Src, 
CDCP1 and FAK do not form a complex in 
adherent HeLa cells (Fig 6D).  
 
Changes in phosphorylation of CDCP1-Y734 
and FAK-Y861 are inversely related during 
changes in attachment of HeLa-CDCP1 cells— 
As it is known that CDCP1-Y734 (20, 23, 29, 
32, 42) and FAK-Y861 are differentially 
phosphorylated during cell adhesion/de-adhesion 
(43), we also used changes in attachment of 
HeLa-CDCP1 cells to initiate changes in 
phosphorylation of these proteins. To examine 
changes occurring during loss of cell adhesion, 
we analysed cells that had been treated with 
EDTA (500 µM) to initiate de-adhesion from 
plastic. To examine changes occurring during 
cell re-adhesion, we analysed cells that had been 
allowed to adhere to plastic after a period of 30 
minutes in suspension. As shown in Figure 7A 
and B, de-adhesion of both HeLa-CDCP1 clone 
2 and 3 resulted in rapid reduction in 
phosphorylation of FAK-Y861 and this was 
accompanied by increasing levels of p-CDCP1-
Y734. These changes were most obvious in 
clone 2 that under basal conditions has the 
highest levels of p-FAK-Y861 and the lowest 
levels of p-CDCP1-Y734. In cell adhesion 
experiments, reduction in phosphorylation of 
CDCP1-Y734 in clone 2 was accompanied by 
increasing p-FAK-Y861 levels (Fig 7C). For 
clone 3, which has higher levels of basal p-
CDCP1-Y734, reduction of phosphorylation of 
this site during cell adhesion was not as apparent 
but p-FAK-Y861 levels increased during the 45 
min attachment period. These data indicate that 
in cells stably expressing CDCP1, 
phosphorylation switching between FAK-Y861 
and CDCP1-Y734 can be induced by changes in 
cell attachment. 
 
SFK switching between FAK-Y861 and CDCP1-
Y734 occurs endogenously in colorectal cancer 
SW480 and HCT116 cells and depends on the 
state of cell adhesion—The above data indicate 
that in HeLa-CDCP1 cells, FAK-Y861 and 
CDCP1-Y734 compete as SFK substrates. We 
next examined competition between these sites 
for SFK phosphorylation in cells endogenously 
expressing FAK and CDCP1. To identify 
appropriate cell lines for this study, we assessed 
the expression of 135 kDa p-CDCP1-Y734 and 
125 kDa p-FAK-Y861 in 4 colon cancer cell 
lines (CaCo2, HCT116, SW480 and SW620). As 
shown in Figure 8A, highest levels of basal 
phosphorylation of CDCP1-Y734 and FAK-
Y861 were seen in SW620 cells with HCT116 
cells showing lower levels of basal 
phosphorylation of these proteins. 
Phosphorylated FAK-Y861 was also detected in 
both SW480 and CaCo2 cells. In these two lines 
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p-CDCP1-Y734 was detectable only in SW480 
cells and at very low levels. Two of the cell lines 
showing intermediate levels of p-CDCP1-Y734 
and p-FAK-Y861, HCT116 and SW480, were 
selected to examine SFK switching in 
endogenous expressing cells. Changes in cell 
adhesion, as described above (Fig 7), were used 
to initiate changes in phosphorylation of these 
proteins. As shown in Figure 8B, de-adhesion of 
SW480 cells resulted in rapid reduction in 
phosphorylation of FAK-Y861 and this was 
accompanied by increasing levels of p-CDCP1-
Y734. Loss of p-FAK-Y861 in response to 
EDTA was even more rapid In HCT116 cells 
and this was accompanied by an increase in p-
CDCP1-Y734 (Fig 8C). In cell adhesion 
experiments, loss of p-CDCP1-Y734 occurred 
within 5 minutes of adhesion to plastic of both 
SW480 and HCT116 cells and this was 
accompanied by a gradual increase in levels of 
p-FAK-Y861 (Fig 8D and E). Of note, the most 
pronounced SFK switching between p-FAK-
Y861 and p-CDCP1-Y734 occurred in SW480 
cells undergoing de-adhesion, which is 
consistent with the low levels of basal 
phosphorylation of p-CDCP1-Y734 seen in 
these cells. 
 
To directly examine interactions between Src 
and FAK, and Src and CDCP1, we also 
performed anti-Src immunoprecipitations. For 
these experiments we employed HCT116 cells 
which express p-CDCP1-Y734 and p-FAK-
Y861 at similar levels under adherent conditions 
(Fig 8A). Immunoprecipitations were performed 
from adhered cells and cells that had undergone 
EDTA induced de-adhesion for 45 minutes as 
well as from cells that had undergone re-
adhesion for 45 minutes after suspension growth 
for 30 minutes. Western blot analysis of lysates 
and anti-Src immunoprecipitated proteins 
indicated that in adhered cells both CDCP1 and 
FAK interact with Src and that both CDCP1 and 
FAK are phosphorylated (Fig 8F). After de-
adhesion, higher levels of CDCP1 and lower 
levels of FAK co-precipitated with Src. It was 
also apparent that while the level of 
phosphorylation of co-precipitating CDCP1-
Y734 increased, co-precipitating FAK-Y861 
was unphosphorylated (Fig 8F). Also consistent 
with a mechanism where Src switches between 
phosphorylation of FAK-Y861 and CDCP1-
Y734, re-adhesion of HCT116 cells resulted in 
immunoprecipitation of lower levels of CDCP1 
and higher levels of FAK with marked reduction 
in p-CDCP1-Y734 levels and re-appearance of 
phosphorylated FAK-Y861 (Fig 8F). Consistent 
data were obtained from HeLa-CDCP1 clone 3 
cells (data not shown).  
 
SFK switching between FAK-Y861 and CDCP1-
Y734 does not involve formation of a 
SFK•CDCP1•PKCδ complex—It has been 
reported that a trimeric SFK•CDCP1•PKCδ 
complex forms in response to a number of 
stimuli including cell de-adhesion (23) and 
CDCP1 proteolysis (33). To examine whether an 
analogous complex of SFK•CDCP1•FAK forms 
during de-adhesion of SW480 and HCT116 
cells, we performed immunoprecipitations using 
anti-CDCP1 and anti-FAK antibodies. To take 
into account that such a complex is likely to be 
transitory during SFK switching, 
immunoprecipitations were performed on lysates 
from both adherent cells as well as cells actively 
undergoing de-adhesion over a 1 hr time course. 
As shown in Supplementary Figure 6, 
immunoprecipitations with both anti-CDCP1 
and anti-FAK antibodies co-immunoprecitated 
Src from SW480 cells. Densitometry analysis of 
two independent experiments indicated that Src 
binding to CDCP1 increased by approximately 5 
fold over the 1 hour time course of cell de-
adhesion (left panel) which was accompanied by 
a rapid reduction in the level of Src bound to 
FAK (right panel). However, both 
immunoprecipitations failed to provide evidence 
of co-immunoprecipitation of CDCP1 and FAK 
during de-adhesion of SW480 cells (Supp Fig 
6A, compare left and right panel). Similar data 
were obtained from the same time course of de-
adhesion of HCT116 cells. In these cells Src 
binding to CDCP1 increased by almost 5 fold 
over the 1 hour time course of cell de-adhesion 
and this was accompanied by a descrease of 
~60% in binding of Src to FAK (Supp Fig 6B). 
Once again there was no evidence indicating 
formation of a SFK•CDCP1•FAK complex in 
these cells (Supp Fig 6B, compare left and right 
panel).  
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Silencing of CDCP1 induces a more epithelial 
morphology and increases p-FAK-Y861 levels in 
SW480 cells—CDCP1 levels were reduced by 
shRNA-mediated silencing to examine the 
relationship between CDCP1, CDCP1-
Y734/FAK-Y861 phosphorylation events and 
cell morphology in colon cancer SW480 cells. 
Quantitative knockdown of CDCP1 resulted in 
increased phosphorylation of p-FAK-Y861 and 
complete loss of the already low levels of p-
CDCP1-Y734 apparent in control (Fig 9A) and 
parental (Fig 8A) SW480 cells. It was also 
accompanied by the change from an elongated 
morphology characteristic of control SW480 
cells to a more epithelial morphology (Fig 9B). 
 
DISCUSSION 
We report evidence for a novel molecular event 
that involves SFK substrate switching between 
Y861 of FAK and Y734 of the transmembrane 
protein CDCP1. Our data suggest that this 
switching can be manifested by at least two 
mechanisms - (i) increased expression of 
CDCP1; and (ii) changes in cell attachment. As 
these events are common to a number of 
cancers, the identified SFK switching 
mechanism may be relevant to malignant 
transformation. Also of note, our light 
microscopy analyses of HeLa cells stably 
expressing CDCP1 and SW480 colorectal cancer 
cells stably silenced for this protein, suggest that 
this SFK switching mechanism is involved in 
altering cell morphology. We saw that while 
stable CDCP1 expression in HeLa cells induces 
a mesenchymal morphology that is dependent on 
CDCP1-Y734, knockdown of CDCP1 in SW480 
cells causes a more epithelial morphology.  
 
Evidence that FAK-Y861 and CDCP1-Y734 
compete as SFK substrates comes from our 
analysis of endogenous expressing colorectal 
cancer cell lines as well as HeLa cells stably 
expressing CDCP1. Whereas HeLa-vector cells, 
which do not endogenously express CDCP1, 
exhibit phosphorylation of FAK-Y861, HeLa-
CDCP1 cells show a complete absence of 
phosphorylation at this site while tyrosine 734 of 
CDCP1 is heavily phosphorylated. The essential 
role for CDCP1-Y734 in SFK switching 
between FAK and CDCP1 was indicated from 
analysis of HeLa-CDCP1-Y734F cells which 
show restored FAK-Y861 phosphorylation and a 
complete loss of tyrosine phosphorylation of 
CDCP1. Also of note, silencing of CDCP1 in 
HeLa-CDCP1 cells restored p-FAK-Y861 levels 
as well as the epithelial morphology reminiscent 
of control HeLa cells. Importantly, we also 
showed that two other CDCP1 tyrosines (Y743 
and Y762), that are known to also be 
phosphorylated by SFKs, do not play a role in 
SFK switching. These changes in 
phosphorylation of FAK-Y861 and CDCP1-
Y734 correlated with changes in the level of 
expression of CDCP1 in four different HeLa cell 
clones. In these clones p-FAK-Y861 levels 
decreased as CDCP1 levels increased, whereas 
p-CDCP1-Y734 levels increased with increasing 
levels of CDCP1.  
 
Significantly, SFK switching between FAK-
Y861 and CDCP1-Y734 was also induced by 
changes in cell attachment of not only HeLa-
CDCP1 cells but also colorectal cancer SW480 
and HCT116 cells. These analyses of cells 
actively undergoing changes in cell attachment 
indicated the dynamic nature of SFK switching 
between FAK-Y861 and CDCP1-Y734. In these 
cells, de-adhesion induced by EDTA results in 
rapid accumulation of p-CDCP1-Y734 with 
concomitant loss of p-FAK-Y861. In re-adhering 
cells the reverse biochemical changes were 
apparent with p-CDCP1-Y734 reducing 5-10 
minutes after commencement of re-adhesion 
with an attendant increase in phosphorylation of 
p-FAK-Y861. Our proposal for a Src switching 
mechanism is also supported by data from anti-
Src immunoprecipitations. We observed 
increased binding of Src to phosphorylated and 
total CDCP1-Y734 after cell de-adhesion with 
concomitant loss of the Src•p-FAK-Y861 
complex. The converse was apparent after cell 
re-adhesion with reduced levels of Src•p-
CDCP1-Y734 and increased levels of Src•p-
FAK-Y861. These data suggest that during 
changes in cell adhesion binding of Src and 
CDCP1-Y734 correlates inversely with Src 
binding to FAK-Y861 and supports a 
mechanism involving Src switching between 
these two substrates. 
 
Our data are largely consistent with a recent 
report from Spassov and colleagues who 
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observed that CDCP1 is tyrosine phosphorylated 
on cell detachment, while proteins involved in 
stabilisation of focal adhesion, FAK and 
paxillin, are dephosphorylated (29). These 
authors proposed that CDCP1 signalling and 
focal adhesion signalling function in opposition 
during changes in cell attachment (29, 44). This 
is consistent with our observations that suggest 
that this opposition defines an SFK-mediated 
switch. Our data provide novel mechanistic 
insight into this switch by now defining CDCP1-
Y734 and FAK-Y861 as particular tyrosines that 
are differentially phosphorylated during SFK-
mediated switching.  
 
A model of molecular events potentially 
associated with this SFK switching are 
summarized in Figure 10. In adhered cells it is 
known that Src binds to p-FAK-Y397 and 
phosphorylates several other FAK tyrosines 
including Y861 (45). Consistent with previous 
reports (20, 23, 29) we have shown here that 
CDCP1-Y734 is rapidly dephosphorylated 
during cell adhesion. However, the protein 
tyrosine phosphatase (PTP) that mediates this 
dephosphorylation is not yet known (Fig 10A). 
Our data indicate that during cell de-adhesion 
Src switches from FAK-Y861 to 
phosphorylation of CDCP1-Y734. The rapid 
loss of phosphorylation of FAK-Y861 during 
this event also indicates the action of an as yet 
unidentified PTP.  
 
In our experiments in which we increased 
expression of CDCP1, we also observed robust 
SFK-mediated phosphorylation of CDCP1-Y734 
that was accompanied by dephosphorylation of 
FAK-Y861 (Fig 10B). Interestingly, whereas we 
showed that HeLa cells stably expressing 
CDCP1 retain phosphorylation of FAK-Y397, 
Spassov and colleagues noted that induction of 
expression of CDCP1 in MDA-MB-468 breast 
cancer cells results in loss of phosphorylation of 
this site (29). As p-FAK-Y397 is required for 
dynamic focal adhesion assembly and 
disassembly (46), this difference in 
phosphorylation of FAK-Y397 may explain, at 
least in part, the different changes in 
morphology induced in HeLa and MDA-MB-
468 cells by CDCP1 expression. While HeLa-
CDCP1 cells acquire a fibroblast-like 
appearance contrasting with the epithelial 
morphology of parental and vector transfected 
cells, MDA-MB-468-CDCP1 cells lose adhesion 
to the underlying matrix. The difference in 
phosphorylation of FAK-Y397 in these cells, 
likely also indicates that the PTP mediating p-
FAK-Y861 dephosphorylation in MDA-MB-468 
cells is absent in HeLa cells.  
 
We also note that whereas we observed 
increased p-FAK-Y861 levels in colon cancer 
SW480 cells silenced for CDCP1, Razorenova et 
al. recently reported that CDCP1 silencing in 
renal cell carcinoma 786-O cells did not alter 
phosphorylation of FAK-Y861 or 4 other FAK 
tyrosines (27). Interestingly, while we saw a 
more epithelial morphology in SW480-
shCDCP1 cells compared to control cells, 
Razorenova et al. did not report a change in 
morphology of 786-O cells after CDCP1 
knockdown. We have not explored the reason 
for these differences. However, we speculate 
that they may indicate that induction of changes 
in cell morphology, caused by reduced CDCP1 
expression, is finely tuned to Src switching 
between FAK-Y861 and CDCP1-Y734. If this is 
correct, an altered cell morphology would only 
be expected where down-regulation of CDCP1 
induces increased levels of p-FAK-Y861.  
 
Consistent with other reports showing that 
substrate binding accentuates phosphorylation of 
Src-Y416 (39-41), our data indicate that Src 
binding to CDCP1-Y734 induces increased p-
Src-Y416 levels. Consistently, an activating 
anti-CDCP1 antibody that induces increased 
phosphorylation of CDCP1-Y734 also increases 
p-Src-Y416 levels (47). These observations from 
cell lines are consistent with in vivo data 
showing that  p-CDCP1-Y734 and p-Src-Y416 
levels are elevated in tumor nodules of gastric 
cancer 44As3 cells during peritoneal invasion in 
mice (30). Also, Liu et al. have shown recently 
that the ability of Src to enhance metastasis of 
melanoma cells in mice is dependent on a “feed-
forward” loop involving CDCP1-Y734-mediated 
enhancement of Src activation (25). 
 
Several recent reports on FAK-Y861 and a 
growing literature on CDCP1, particularly 
CDCP1-Y734, indicate that SFK switching 
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between FAK-Y861 and CDCP1-Y734 will be 
relevant in physiological and pathological 
settings including those requiring changes in cell 
attachment. For example, FAK-Y861 is 
phosphorylated under disparate conditions that 
are most clearly linked with changes in cell 
attachment. This site is phosphorylated in mouse 
mammary NMuMG cells during both migration 
and  TGF β1-induced EMT (48). Also, 
phosphorylation of FAK-Y861 is induced in 
HeLa cells grown on collagen (49), and in 
endothelial cells by vascular endothelial growth 
factor (50). In prostate cancer LNCaP cells, this 
site is dephosphorylated in cells grown in 
suspension, whereas in other prostate cancer 
lines, PC3 and DU145, changes in adhesion do 
not alter p-FAK-Y861 levels (51). In addition, 
SFK-mediated phosphorylation of FAK-Y861 
and subsequent re-organisation of filamentous 
actin can initiate an anti-apoptotic cascade that 
protects a range of epithelial cells from 
hyperosmotic stress (52). Further, while 
phosphorylation of other FAK tyrosines was 
largely unaltered, p-FAK-Y861 levels increased 
markedly on formation of rat bladder tumor 
NBT-II cell-cell contacts (43). 
 
In contrast with FAK-Y861 which does not have 
a clearly defined pathological role, dysregulated 
CDCP1 expression is associated with cancer 
progression and CDCP1-Y734 is known to 
mediate cancer promoting phenotypes in vitro 
and in vivo. For example, increased CDCP1 
levels correlate with poor prognosis in lung 
cancer (53), renal cell carcinoma (54) and 
pancreatic cancer (26) while studies of small 
numbers of patients indicate that elevated 
CDCP1 expression may also occur in colorectal 
(19,55) and breast (56) cancer. Consistent with a 
functional role in human malignancies for SFK-
mediated switching between phosphorylation of 
FAK-Y861 and CDCP1-Y734, levels of this 
second phospho-tyrosine are elevated in human 
gastric cancers in tumor cells invading the 
gastric wall (30) and in lung cancer patient 
samples p-CDCP1-Y734 is largely present in 
invading tumor cells (53). CDCP1-Y734 has 
also been shown to regulate anoikis of lung 
cancer cells in vitro via a mechanism involving 
recruitment of PKCδ to CDCP1-Y762 and the 
formation of a SFK•CDCP1•PKCδ complex 
(23). In addition, this site regulates in vitro 
pancreatic cancer cell migration, invasion, and 
extracellular matrix degradation in a tyrosine 
phosphorylation- and PKCδ-dependent manner 
(26) and CDCP1-Y734 is required for melanoma 
cell dispersive growth in vitro and metastasis in 
mice (25). Our data and previous reports indicate 
that formation of the SFK•CDCP1•PKCδ 
complex can be driven by at least three 
mechanisms that are often dysregulated in 
cancer: cell de-adhesion (23), proteolysis 
mediated by serine proteases (33) and, as shown 
in this report, over-expression of CDCP1.  
 
In summary, we have demonstrated a novel SFK 
switching mechanism between the substrates 
FAK-Y861 and CDCP1-Y734. In settings of 
increased expression of CDCP1 and loss of cell 
attachment, SFK almost exclusively 
phosphorylates CDCP1-Y734 in preference to 
FAK-Y861. Therapeutic targeting of this SFK 
switch may be a rational approach to treating 
diseases such as cancer. 
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FOOTNOTES 
1The abbreviations used are: CDCP1, CUB-domain containing protein 1; CST, Cell Signaling 
Technology; EDTA, ethylene diamine tetra-acetic acid; EMT, epithelial-mesenchymal transition; FAK, 
focal adhesion kinase; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; SFK, Src family kinase. 
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FIGURE LEGENDS 
FIGURE 1. CDCP1 expression alters HeLa cell morphology dependent on the SFK binding site. 
Analysis of HeLa cells stably transfected with vector or expression constructs encoding either CDCP1 or 
CDCP1-Y734F. A, Anti-FLAG, -CDCP1 (10D7), -Src, - PKCδ and -GAPDH Western blot analysis. B, 
Flow cytometry analysis using the anti-CDCP1 monoclonal antibody 10D7. C, Anti-FLAG, -Src, -
phospho(p)-tyrosine and -PKCδ Western blot analysis of proteins immunoprecipitated from HeLa-vector, 
HeLa-CDCP1 and HeLa-CDCP1-Y734F cells using the monoclonal anti-CDCP1 antibody 41-2. D, 
Transmitted light microscopy analysis. Cells were imaged using a Nikon Eclipse TE2000-U microscope 
(Bar, 100 µm). To quantify the effect of CDCP1 expression on HeLa cell morphology, a shape factor was 
determined for each cell using MetaMorph software as described in Experimental Procedures. At least 50 
cells (for each of three independent cell platings) were analysed for each cell type and cells were grouped 
into the two shape factor categories 0 to 0.49 and 0.5 to 1. These categories were graphed against the 
proportion of cells in each category. Black, HeLa-vector cells; dark grey, HeLa-CDCP1 cells; light grey, 
HeLa-CDCP1-Y734F cells. *, P < 0.05. 
 
FIGURE 2. Knock-down of CDCP1 reverts HeLa-CDCP1 cells to an epithelial morphology. A, 
HeLa-vector, HeLa-CDCP1 and HeLa-CDCP1-Y734F cells were stably transfected with either a CDCP1 
shRNA knockdown construct or a scramble control construct. Lysates of these cells were examined by 
anti-CDCP1 (#4115) and anti-tubulin Western blot analysis. To facilitate comparison, the anti-CDCP1 
and -tubulin panels are also displayed in Figure 5B with contemporaneously performed anti-p-FAK-Y861 
and -FAK Western blot analyses. B, Transmitted light microscopy analysis. Cells were imaged using a 
Nikon Eclipse TE2000-U microscope. Arrow, epithelial morphology; arrowhead, elongated, fibroblastic 
morphology. Bar, 100 µm. 
 
FIGURE 3. CDCP1-induced HeLa cell morphology change requires SFK activity. A, Transmitted 
light microscopy analysis. HeLa-vector, HeLa-CDCP1 and HeLa-CDCP1-Y734F cells were treated with 
vehicle (DMSO 0.075% v/v; control)  or the SFK selective inhibitor SU6656 (10 µM) for 1 hour. The 
media was then changed to normal growth media and after another 23 hrs cells were imaged using a 
Nikon Eclipse TE2000-U microscope. Arrow, epithelial morphology; arrowhead, elongated, fibroblastic 
morphology. Images are representative of 3 independent experiments. B, Graph of percentage of cells 
versus cell shape factor determined using MetaMorph software analysis as described in Experimental 
Procedures. Black, HeLa-vector cells; dark grey, HeLa-CDCP1 cells; light grey, HeLa-CDCP1-Y734F 
cells. C, Graphical representation of flow cytometry analysis of cells following SU6656 treatment (10 µM 
1 hr) and re-equilibration for a further 23 hrs. Cells were lifted and the percentage of cells undergoing 
apoptosis was assessed by flow cytometry analysis of cells stained with Alexa Fluor 647 conjugated 
annexin V. The data are from 3 experiments performed in triplicate. Black, HeLa-vector cells; dark grey, 
HeLa-CDCP1 cells; light grey, HeLa-CDCP1-Y734F cells. 
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FIGURE 4. Altered HeLa-CDCP1 cell morphology is accompanied by increased phosphorylation of 
Src-Y416 without altering cellular localisation of CDCP1 or Src. A, Anti-FLAG, -Src, -p-Src-Y416 
and -tubulin Western blot analysis of lysates from HeLa-vector, HeLa-CDCP1 and HeLa-CDCP1-Y734F 
cells. This analysis is representative of 4 independent experiments. Data from densitometric analysis of p-
Src-Y416 signal relative to total Src signal from 4 independent experiments are graphed at the bottom. *, 
P < 0.05. B, Confocal microscopy analysis. HeLa-vector, HeLa-CDCP1 and HeLa-CDCP1-Y734F cells 
were incubated with anti-CDCP1 and -Src antibodies followed by species-specific secondary antibodies 
then stained with phalloidin conjugated Alexa Fluor 488 and DAPI to visualise actin and cell nuclei, 
respectively. Images were acquired using a Leica SP5 confocal microscope. Bar, 25 µm. 
 
FIGURE 5. CDCP1-Y734 is phosphorylated in preference to FAK-Y861 in HeLa-CDCP1 cells. A, 
Anti-p-FAK-Y861 (which also recognises p-CDCP1-Y734; (20)), p-FAK-Y397, -FAK, -FLAG and 
GAPDH Western blot analysis of lysates from HeLa-vector, HeLa-CDCP1 and HeLa-CDCP1-Y734F 
cells. B, HeLa-vector, HeLa-CDCP1 and HeLa-CDCP1-Y734F cells were stably transfected with either a 
CDCP1 shRNA knockdown construct or a scramble control construct. Lysates of these cells were 
examined by Western blot analysis using antibodies against CDCP1 (#4115), p-FAK-Y861, FAK  and 
tubulin. These analyses were performed contemporaneously and anti-CDCP1 and -tubulin panels are also 
shown in Figure 2A to facilitate comparison. C, HeLa-vector, HeLa-CDCP1 and HeLa-CDCP1-Y734F 
cells were treated with vehicle (DMSO 0.37% v/v; 0) or with the indicated concentrations of the SFK 
inhibitor SU6656 for 60 min. Lysates were analysed by Western blot analysis using antibodies against p-
FAK-Y861, FAK, FLAG and tubulin.  
 
 
FIGURE 6. Phosphorylation of CDCP1-Y734 and FAK-Y861 in HeLa-CDCP1 cells is inversely 
related and depends on the level of expression of CDCP1, but CDCP1 and FAK do not interact. 
Analysis of four HeLa cell clones stably expressing different levels of CDCP1. A, Anti-CDCP1 (antibody 
10D7) flow cytometry analysis of four HeLa-CDCP1 cell clones (numbered 1 to 4) that express CDCP1 
at increasing levels. HeLa-vector and prostate cancer PC3 cells were analysed as negative and positive 
controls for CDCP1 expression (dotted lines). The mean fluorsence intensity (Mean-FI) for each cell line 
is shown. B, Western blot analysis of lysates from HeLa-CDCP1 cell clones using anti-FLAG, -p-FAK-
Y861 (which also recognises p-CDCP1-Y734; (20)), -p-FAK-Y397, -FAK, Src and -GAPDH antibodies. 
Phospohorylated CDCP1-Y734 and FAK-Y861 are indicated by arrows. C, Transmitted light microscopy 
analysis. Cells were imaged using an Olympus XX-41 microscope. Arrow, epithelial morphology; 
arrowhead, elongated, fibroblastic morphology. D, Western blot analysis of lysates and proteins 
immunoprecipitated with an anti-FLAG antibody from HeLa-vector, HeLa-CDCP1 and HeLa-CDCP1-
Y734F (clone 4) cells using antibodies against FLAG, FAK, p-tyrosine and tubulin. 
 
FIGURE 7. Changes in phosphorylation of CDCP1-Y734 and FAK-Y861 are inversely related 
during changes in attachment of HeLa-CDCP1 cells. Lysates from HeLa-CDCP1 cells undergoing 
either de-adhesion induced by EDTA over 45 minutes or re-adhesion over 45 minutes (after suspension 
growth for 30 minutes) were analysed by Western blot analysis using antibodies against p-FAK-Y861 
(which also recognises p-CDCP1-Y734; (20)), CDCP1 (#4115), FAK and tubulin. A, HeLa-CDCP1 clone 
2 cells undergoing de-adhesion. B, HeLa-CDCP1 clone 3 cells undergoing de-adhesion. C, HeLa-CDCP1 
clone 2 cells undergoing re-adhesion. D, HeLa-CDCP1 clone 3 cells undergoing re-adhesion. The data in 
A-D are representative of 2 independent experiments. 
 
FIGURE 8. Changes in phosphorylation of CDCP1-Y734 and FAK-Y861 are inversely related 
during changes in attachment of SW480 and HCT116 cells. A, Anti-p-FAK-Y861 (which also 
recognises p-CDCP1-Y734; (20)), -CDCP1, -FAK, -Src and -GAPDH Western blot analysis of lysates 
from colon cancer Caco2, HCT116, SW480 and SW620 cells. B-C, Anti-p-FAK-Y861, -CDCP1, -FAK 
and -GAPDH Western blot analysis of lysates from adherent cells and cells treated for up to 45 minutes 
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with EDTA. D-E, Anti-p-FAK-Y861, -FAK , -CDCP1 and -GAPDH Western blot analysis of lysates 
from cells maintained in suspension for 30 min and cells undergoing re-adhesion for up to 45 minutes. 
The data in B-E are representative of at least 3 independent experiments. F, Western blot analysis of 
lysates (input; left) and anti-Src immunoprecipitates (right) from HCT116 cells either grown adhered, 
treated for 45 minutes with EDTA (De-adhered) or cells undergoing re-adhesion for up to 45 minutes 
(Re-adhered). Lysates and immunoprecipitated proteins were analysed with anti-CDCP1, -FAK, -p-FAK-
Y861 and -Src antibodies and lysates were also examined with an anti-tubulin antibody. 
 
FIGURE 9. Silencing of CDCP1 in SW480 cells induces a more epithelial morphology and increases 
p-FAK-Y861 levels. A, SW480 cells were stably transfected with either a CDCP1 shRNA knockdown 
construct or a scramble control construct. Lysates of these cells were examined by Western blot analysis 
using antibodies against CDCP1 (#4115), FAK, p-FAK-Y861 and tubulin. Longer exposures of the anti-
p-FAK-Y861 blot shows p-CDCP1-Y734 in scramble control cells but these mask the increase in p-FAK-
Y861 levels that accompanies knockdown of CDCP1. B, Transmitted light microscopy analysis. Cells 
were imaged using a Nikon Eclipse TE2000-U microscope. Arrow, epithelial morphology; arrowhead, 
elongated, fibroblastic morphology. Bar, 100 µm,  
 
 
FIGURE 10. SFK switching between FAK-Y861 and CDCP1-Y734. A, In adherent cells Src binds to 
p-FAK-Y397 and phosphorylates several other FAK tyrosines including Y861 (45). We and others 
(20,23,29) have shown that CDCP1-Y734 is rapidly dephosphorylated during cell adhesion but the 
protein tyrosine phosphatase (PTP) that mediates this dephosphorylation is not yet known. Src 
phosphorylation of CDCP1-Y734 also results in increased phosphorylation of Src-Y416. In de-adhered 
cells our data indicate that Src switches to phosphorylation of CDCP1-Y734 and we have shown that 
FAK-Y861 is rapidly dephosphorylated in this setting. The PTP that mediates FAK-Y861 
dephosphorylation is also not known. B, In cells with elevated expression of CDCP1, Src phosphorylates 
CDCP1-Y734 which is accompanied by dephosphoryation of FAK-Y861. In HeLa cells stably expressing 
CDCP1 phosphorylation of FAK-Y397 is maintained, indicating that the kinase activity of FAK and its 
role in focal adhesion is retained. 
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